biotech / news / / The Irish Times
Wegovy maker Novo Nordisk said surging demand for its first weight loss pill has put it on track to beat trading forecasts.
Novo Nordisk's Wegovy pill launch saw over two million prescriptions since January in the US.
KEY POINTS
- The Wegovy pill generated €300 million in Q1 sales, surpassing analyst expectations.
- Novo Nordisk plans international Wegovy pill launches outside the US in the second half of 2026.
- Adjusted sales guidance for the year improved, with projected dips reduced from 13% to 12%.
COMPANIES
Summarized by Newsio from The Irish Times. How we summarize →